First human trial for genetic eye disease treatment begins
NCT ID NCT06970106
Summary
This early-stage study is testing the safety of a new eye injection called PYC-001 in adults with a specific genetic condition that causes progressive vision loss (OPA1-related optic atrophy). About 21 participants in the UK and Australia will receive different doses and schedules of the injection to find the safest and most suitable regimen. The main goal is to see how well the treatment is tolerated and to gather initial data on its effect on eye structure and vision.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPA1 GENE MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cerulea Clinical Trials
RECRUITINGEast Melbourne, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Retina Specialists
RECRUITINGAuckland, 1052, New Zealand
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Save Sight Institute - Sydney Eye Hospital
RECRUITINGSydney, New South Wales, 2000, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.